Vertex Pharmaceuticals Incorporated (VRTX) CMO Sells $39,863.81 in Stock
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Reshma Kewalramani sold 241 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $165.41, for a total transaction of $39,863.81. Following the sale, the chief marketing officer now owns 13,736 shares in the company, valued at approximately $2,272,071.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Reshma Kewalramani also recently made the following trade(s):
- On Tuesday, February 19th, Reshma Kewalramani sold 1,488 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $186.94, for a total transaction of $278,166.72.
Vertex Pharmaceuticals stock traded down $1.50 during trading hours on Friday, hitting $168.73. The company had a trading volume of 896,463 shares, compared to its average volume of 1,079,231. The firm has a market cap of $43.60 billion, a PE ratio of 52.70, a P/E/G ratio of 2.47 and a beta of 1.56. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.66 and a current ratio of 3.78. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $144.07 and a fifty-two week high of $195.81.
A number of research firms have recently issued reports on VRTX. Zacks Investment Research upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, January 26th. ValuEngine upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, May 1st. BidaskClub lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. BMO Capital Markets boosted their price target on shares of Vertex Pharmaceuticals to $234.00 and gave the company an “outperform” rating in a report on Wednesday, February 6th. Finally, JPMorgan Chase & Co. restated a “buy” rating and set a $209.00 price target on shares of Vertex Pharmaceuticals in a report on Wednesday, May 1st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and fifteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $203.35.
A number of institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its position in Vertex Pharmaceuticals by 19.3% in the first quarter. FMR LLC now owns 24,434,159 shares of the pharmaceutical company’s stock worth $4,494,663,000 after acquiring an additional 3,951,050 shares in the last quarter. BlackRock Inc. grew its position in Vertex Pharmaceuticals by 2.9% in the first quarter. BlackRock Inc. now owns 20,176,298 shares of the pharmaceutical company’s stock worth $3,711,428,000 after acquiring an additional 568,488 shares in the last quarter. Vanguard Group Inc grew its position in Vertex Pharmaceuticals by 1.2% in the third quarter. Vanguard Group Inc now owns 18,775,252 shares of the pharmaceutical company’s stock worth $3,618,743,000 after acquiring an additional 213,550 shares in the last quarter. Wellington Management Group LLP grew its position in Vertex Pharmaceuticals by 2.4% in the first quarter. Wellington Management Group LLP now owns 8,828,785 shares of the pharmaceutical company’s stock worth $1,624,056,000 after acquiring an additional 210,383 shares in the last quarter. Finally, Jennison Associates LLC grew its position in Vertex Pharmaceuticals by 11.9% in the fourth quarter. Jennison Associates LLC now owns 6,941,621 shares of the pharmaceutical company’s stock worth $1,150,296,000 after acquiring an additional 739,128 shares in the last quarter. Hedge funds and other institutional investors own 94.92% of the company’s stock.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
See Also: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.